SC
DYN icon

Stempoint Capital’s Dyne Therapeutics DYN Stock Holding History

Stempoint Capital’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-506,075
Closed -$9.18M – 90
2026
Q1 		$9.18M Sell
506,075
-329,125
-39% -$5.68M 1.76% 18
2025
Q4 		$16.3M Buy
835,200
+360,588
+76% +$6.83M 2.8% 11
2025
Q3 		$6M Buy
+474,612
New +$5.41M 1.2% 26
2025
Q2 		– Sell
-84,430
Closed -$883K – 62
2025
Q1 		$883K Buy
+84,430
New +$1.21M 0.28% 45

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Stempoint Capital's DYN Position: Q2 2026 in Review

Stempoint Capital sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 506,075 shares — an estimated $9.18M sold.

Stempoint Capital first reported a position in DYN in Q1 2025 and held it in 4 quarters. The position peaked at $16.3M in Q4 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Stempoint Capital reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stempoint Capital sold 506,075 Dyne Therapeutics shares in Q2 2026, an estimated $9.18M.
  • Stempoint Capital first reported a position in Dyne Therapeutics in Q1 2025 and held it in 4 quarters.
  • Stempoint Capital's Dyne Therapeutics position peaked at $16.3M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.